MARKET

PKI

PKI

Perkinelmer
NYSE

Real-time Quotes | Nasdaq Last Sale

142.49
-5.14
-3.48%
After Hours: 142.49 0 0.00% 16:27 05/18 EDT
OPEN
144.09
PREV CLOSE
147.63
HIGH
145.26
LOW
141.07
VOLUME
776.40K
TURNOVER
21.09M
52 WEEK HIGH
203.16
52 WEEK LOW
137.37
MARKET CAP
17.97B
P/E (TTM)
22.99
1D
5D
1M
3M
1Y
5Y
--Barclays Starts PerkinElmer at Underweight With $125 Price Target
MT Newswires · 18h ago
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
Zacks · 05/04 14:54
Research Alert: CFRA Keeps Hold Opinion On Shares Of Perkinelmer Inc.
MT Newswires · 05/04 10:57
Recap: PerkinElmer Q1 Earnings
PerkinElmer (NYSE:PKI) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings PerkinElmer beat estimated earnings by 15.87%, reporting an EPS of $2.41 versus an estimate of ...
Benzinga · 05/03 21:39
PerkinElmer (PKI) Beats Q1 Earnings and Revenue Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of 15.87% and 6.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 21:25
BRIEF-Perkinelmer Announces Financial Results For The First Quarter Of 2022
reuters.com · 05/03 20:36
PerkinElmer Non-GAAP EPS of $2.41 beats by $0.29, revenue of $1.26B beats by $70M
PerkinElmer press release (NYSE:PKI): Q1 Non-GAAP EPS of $2.41 beats by $0.29. Revenue of $1.26B (-3.8% Y/Y) beats by $70M. Initiates Q2 and Raises 2022 Guidance: The Company forecasts revenue of
Seekingalpha · 05/03 20:27
PerkinElmer Q1 Adj. EPS $2.41 Beats $2.08 Estimate, Sales $1.26B Beat $1.18B Estimate
PerkinElmer (NYSE:PKI) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.08 by 15.87 percent. This is a 35.22 percent decrease over earnings of $3.72 per share from the same
Benzinga · 05/03 20:09
More
No Data
Learn about the latest financial forecast of PKI. Analyze the recent business situations of Perkinelmer through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.77%Strong Buy
7.69%Buy
61.54%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PKI stock price target is 184.00 with a high estimate of 200.00 and a low estimate of 167.00.
High200.00
Average184.00
Low167.00
Current 142.49
EPS
Actual
Estimate
0.711.422.122.83
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 823
Institutional Holdings: 126.76M
% Owned: 100.48%
Shares Outstanding: 126.15M
TypeInstitutionsShares
Increased
226
9.80M
New
111
684.79K
Decreased
189
4.19M
Sold Out
63
1.10M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.89%
Healthcare Equipment & Supplies
-2.33%
Key Executives
Non-Executive Chairman/Independent Director
Alexandros Michas
President/Chief Executive Officer/Director
Prahlad Singh
Chief Financial Officer/Senior Vice President
James Mock
Senior Vice President/General Counsel/Secretary
Joel Goldberg
Senior Vice President
Daniel Tereau
Senior Vice President
Miriame Victor
Senior Vice President
Tajinder Vohra
Chief Accounting Officer/Vice President/Treasurer
Andrew Okun
Independent Director
Peter Barrett
Independent Director
Samuel Chapin
Independent Director
Sylvie Gregoire
Independent Director
Michel Vounatsos
Independent Director
Frank Witney
Independent Director
Pascale Witz
No Data
No Data
About PKI
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and Haoyuan.

Webull offers kinds of PerkinElmer, Inc. stock information, including NYSE:PKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PKI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PKI stock methods without spending real money on the virtual paper trading platform.